The Full Wiki

More info on Fipexide

Fipexide: Wikis

Advertisements
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Fipexide
Systematic (IUPAC) name
1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-
2-(4-chlorophenoxy)ethanone
Identifiers
CAS number 34161-24-5
ATC code N06BX05
PubChem 3351
Chemical data
Formula C 20H21ClN2O4  
Mol. mass 388.845 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Fipexide (Attentil, Vigilor) is a psychoactive drug of the piperazine chemical class which was developed in Italy in 1983.[1] It was used as a nootropic drug in Italy and France, mainly for the treatment of senile dementia,[2] but is no longer in common use due to the occurrence of rare adverse drug reactions including fever[3] and hepatitis. Fipexide is similar in action to other nootropic drugs such as piracetam and is structurally similar to another more well-known nootropic, centrophenoxine. Chemically, it is an amide union of parachlorophenoxyacetate and methylenedioxybenzylpiperazine, and notably, has been shown to metabolize to the latter, which plays a significant role in its effects.

See also

References

  1. ^ Missale C, Pasinetti G, Govoni S, Spano PF, Trabucchi M. Fipexide: a new drug for the regulation of dopaminergic system at the macromolecular level. Bollettino Chimico Farmaceutico. 1983 Feb;122(2):79-85.
  2. ^ Bompani R, Scali G. Fipexide, an effective cognition activator in the elderly: a placebo-controlled, double-blind clinical trial. Current Medical Research and Opinion. 1986;10(2):99-106.
  3. ^ Guy C, Blay N, Rousset H, Fardeau V, Ollagnier M. Fever caused by fipexide. Evaluation of the national pharmacovigilance survey. Therapie. 1990 Sep-Oct;45(5):429-31.
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message